Based on the results, iTeos and GSK are stopping all ongoing trials of belrestotug, including an ongoing Phase 3 study in lung cancer. iTeos is “taking immediate steps to preserve capital” as ...

On July 7, 2025, iTeos Therapeutics, Inc. (NASDAQ:ITOS) stock closed at $10.07 per share, with a market capitalization of $385.417 million.

“As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we’re excited to welcome Dr. Feltquate as Chief Medical Officer,” said Michel ...

Turning to iTeos Therapeutics' balance sheet, the company had cash and cash equivalents of $216.2M, short-term investments of $383.0M, and long-term investments of $78.3M as of June 30, 2023.

iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

iTeos Therapeutics Price Performance NASDAQ ITOS opened at $7.50 on Friday. The firm has a market capitalization of $286.46 million, a P/E ratio of -2.38 and a beta of 1.43. iTeos Therapeutics has ...

WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...

In April, iTeos said its cash and investments position was $624.3 million as of March 31, 2025, which is expected to provide a cash runway into 2027. Price Action: ITOS stock is up 17.3% at $8.12 ...

Biotech iTeos brings on Sanofi cancer VP as CMO as it wades deeper into the clinic By Conor Hale Mar 26, 2019 10:25am chief medical officer clinical research immuno-oncology iTeos Therapeutics ...

GSK and iTeos will share in the work and the expenses for global development of EOS-448, according to the agreement. They’ll also share in commercializing the drug—if it’s approved.

iTeos Therapeutics has raised $75 million (€64 million) to take two immuno-oncology assets into the clinic. The MPM Capital-led series B tees iTeos up to start dosing patients with an adenosine ...